Immunophenotypic markers shown in various studies implicating adverse outcomes are CD7, CD9, CD11b, CD13, CD14, CD33, CD34, CD56 and terminal deoxynucleotidyl transferase.8 Regardless of the increasing importance of molecular and genetic features in the sub classification of acute leukemias, morphology and immunophenotyping remain the primary modalities by which leukemias are evaluated.9 This evidence concerns the gene CD7 and leukemia.